Company intelligence / Profile preview

UTILITY therapeutics

Altrincham, England, United Kingdomutilitytherapeutics.com ↗

Ownership: Private
Development stage: NDA

Overview

FDA approved PIVYA (pivmecillinam) for treatment of female adults with uncomplicated UTIs on April 25, 2024. Clinical trials showed 62% of 137 subjects achieved composite response compared to 10% with placebo. In another trial, 72% of 127 subjects achieved composite response compared to 76% with a comparator drug. In a third trial, 66% of 105 subjects achieved composite response compared to 22% with ibuprofen[5].

Therapeutic areas: Infectious Diseases
Modalities: Small moleculesAntibiotics
Industry: Biotech

Drug pipeline

2 assets

pivmecillinam

Approved

1 more asset in the full pipeline.

Request access →

Partnerships

LEO Pharma A/S (license agreement for US rights to mecillinam and pivmecillinam)[6]

Beyond the preview

Go deeper on UTILITY therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UTILITY therapeutics.

Explore the full profile